Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Restructuring Costs: 2022-2023

Historic Restructuring Costs for Ani Pharmaceuticals (ANIP) over the last 1 years, with Jun 2023 value amounting to $2,000.

  • Ani Pharmaceuticals' Restructuring Costs fell 99.92% to $2,000 in Q2 2023 from the same period last year, while for Jun 2023 it was $4.2 million, marking a year-over-year change of. This contributed to the annual value of $1.1 million for FY2023, which is 80.07% down from last year.
  • Latest data reveals that Ani Pharmaceuticals reported Restructuring Costs of $2,000 as of Q2 2023, which was down 99.82% from $1.1 million recorded in Q1 2023.
  • Over the past 5 years, Ani Pharmaceuticals' Restructuring Costs peaked at $2.6 million during Q2 2022, and registered a low of $2,000 during Q2 2023.
  • For the 2-year period, Ani Pharmaceuticals' Restructuring Costs averaged around $1.4 million, with its median value being $1.5 million (2022).
  • Data for Ani Pharmaceuticals' Restructuring Costs shows a maximum YoY slumped of 99.92% (in 2023) over the last 5 years.
  • Quarterly analysis of 2 years shows Ani Pharmaceuticals' Restructuring Costs stood at $1.6 million in 2022, then plummeted by 99.92% to $2,000 in 2023.
  • Its Restructuring Costs stands at $2,000 for Q2 2023, versus $1.1 million for Q1 2023 and $1.6 million for Q4 2022.